Why the study?
Does methotrexate improve blood pressure and markers of arterial function in patients with rheumatoid arthritis?
Population
86 patients with rheumatoid arthritis on stable treatment, including 56 on MTX ± other DMARDs and 30 on…
Comparison
Methotrexate ± other disease-modifying… vs Other disease-modifying antirheumatic drugs…
Design
Cross-sectional
Follow-up
8 months
Key result
Methotrexate treatment in rheumatoid arthritis was associated with significantly lower clinic peripheral systolic blood pressure versus other DMARDs (MD -7.7 mmHg; 95% CI -13.2 to -2.3; p=0.006).
Authors
Loading...
Supports potential vascular benefit of methotrexate in RA; leaves open whether this improves CV outcomes in prospective trials.
Cross-Sectional (n=86)
Does methotrexate improve blood pressure and markers of arterial function in patients with rheumatoid arthritis?
Mean Difference: -7.7 (95% CI -13.2–-2.3)
p-value: p=0.006
Methotrexate use in rheumatoid arthritis is associated with significantly lower peripheral and central blood pressure and improved pulse wave velocity compared to other DMARDs, suggesting a potential mechanism for its cardioprotective effects.
Mangoni et al. (2017) conducted a cross-sectional in rheumatoid arthritis (n=86). Methotrexate vs. Other DMARDs was evaluated on Clinic peripheral systolic blood pressure (MD -7.7 mmHg, 95% CI -13.2 to -2.3, p=0.006). Methotrexate treatment in rheumatoid arthritis was associated with significantly lower clinic peripheral systolic blood pressure versus other DMARDs (MD -7.7 mmHg; 95% CI -13.2 to -2.3; p=0.006).